Janux Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -5.05M-32.67M-63.06M-58.29M-68.99M
Depreciation and Depletion 0.01M0.11M0.84M1.96M2.06M
Share-based Compensation 0.07M6.91M17.20M20.00M33.02M
Gains from Sales and Divestitures 0.00M
Gains from Investment Securities 1.10M5.65M7.35M7.99M8.87M
Non-cash Items 3.21M5.07M4.95M5.23M5.40M
Cash from Operations -4.37M-16.98M-42.92M-50.58M-43.81M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.17M2.18M7.69M10.59M
Depreciation & Amortization (CF) 0.01M0.11M0.84M1.96M2.06M
Change in Working Capital
Change in Receivables 8.00M-8.00M
Change in Account Payables 0.01M2.14M-0.29M0.28M1.58M
Change in Accured Expenses 0.62M3.03M4.16M-0.68M4.43M
Investing Activities
Capital Expenditures 0.15M1.48M6.45M1.85M0.36M
Change in Acquisitions & Divestments 134.15M359.10M278.00M212.91M
Cash from Investing Activities -340.96M58.27M-41.19M-258.02M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Issuances 8.95M124.83M
Change in Capital Stock
Shares Issued 204.17M
Misc.
Cash from Financing Activities 11.52M386.52M0.50M59.55M713.24M
Change in Cash 7.16M28.59M15.84M-32.22M411.40M
Free Cash Flow -4.52M-18.46M-49.37M-52.42M-44.17M
Net Cash Flow 7.16M28.59M15.84M-32.22M411.40M